Patents Examined by Jennifer M. H. Tichy
  • Patent number: 10428311
    Abstract: The present invention provides a novel technique in a cell culture method using a cell culture vessel coated with a laminin fragment, which novel technique achieves cell culture as in the case of using a recommended coating concentration even when the coating concentration is lower than the recommended coating concentration. The present invention relates to a method for enhancing an activity for mammalian cultured cells of a laminin fragment or a variant thereof each having integrin binding activity.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: October 1, 2019
    Assignee: OSAKA UNIVERSITY
    Inventors: Kiyotoshi Sekiguchi, Ko Tsutsui
  • Patent number: 10421777
    Abstract: Polyelectrolyte based bioactive super-absorbent material ionotropically crosslinked/neutralized involving polyvalent carboxylic acids, citrate, Kojic Acid, Alpha Arbutin along with fish scale collagen cross linked with other polyelectrolyte biopolymers preferably selected from chitosan, alginate or their combinations is used in this invention. The advancement is also directed to process of extraction of collagen of high purity from fresh water fish scale by salt and alkaline washing, crushing followed by continuous dialysis thereby minimizing the chance of collagen degradation. Also disclosed are different forms of collagen-chitosan composite biomaterial using citrate as the neutralizing buffer in combination with antimicrobial agent, antioxidant, skin plumper and melanin reducer wherein the different forms of collagen chitosan particularly sheet, flakes, powder, gel, particles, fiber, film, spray etc. reveal efficient wound healing properties.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: September 24, 2019
    Assignee: Amnivor Medicare Private Limited
    Inventors: Santanu Dhara, Pallab Majumdar, Nilanjana Maiti
  • Patent number: 10415014
    Abstract: A method for the ex vivo cultivation of oral mucosal epithelial progenitor cells and oral mucosal epithelial cells includes: subjecting an oral mucosal tissue to an enzymatic digestion treatment with collagenase, so as to obtain cell aggregates which include oral mucosal epithelial progenitor cells and oral mucosal epithelial cells; cultivating the cell aggregates with an amniotic membrane in a serum-free platelet lysate-containing medium in the absence of feeder cells, so that the cell aggregates are adhered onto the amniotic membrane; and subsequently cultivating the cell aggregates adhered on the amniotic membrane in a serum-free proliferation-facilitating medium in the absence of feeder cells.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: September 17, 2019
    Assignee: Chang Gung Memorial Hospital, Linkou
    Inventors: Hui-Kang Ma, Shih-Chieh Ma
  • Patent number: 10383338
    Abstract: Compositions and uses involving L. monocytogenes PssZ, as well as homologs, variants, and fragments thereof, are described.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: August 20, 2019
    Assignee: University of Wyoming
    Inventors: Mark Gomelsky, Kurt Miller, Volkan Köseo{hacek over (g)}lu
  • Patent number: 10376548
    Abstract: Compositions and methods are provided for improving the health of an animal by reducing certain diseases and by binding certain heavy metals that may be unintentionally introduced into the body of the animal from the environment. Compositions and methods are also provided for improving the feed conversion ratio of an animal. In addition, compositions and methods are provided for reducing nitrate pollution in the environment. In one embodiment, the composition may include mastic gum, a mixture of ionic minerals, and optionally an essential amino acid not produced by the animal. The ionic minerals may be derived from water sourced from an inland sea such as the Great Salt Lake, the Dead Sea, or another inland sea. The essential amino acid may be included in the form of a protein. The animal may be a ruminant, poultry, or other animal. Methods are also provided for processing mastic gum.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: August 13, 2019
    Assignee: ABSORBEZZ, LLC
    Inventors: Joseph Scivoletto, Steven Adelstein
  • Patent number: 10351823
    Abstract: Methods for producing a population of human-derived glial restricted progenitor cells (GRPs) with decreased potentially unintended or undesired cellular phenotypes and/or decreased standard deviation in the cells of the population are provided. Also provided are antibody panels and gene expression profiles to characterize GRPs and a method for its use in characterizing GRP cells. In addition methods for use of these GRP cells to generate astrocytes and/or oligodendrocytes, to re-myelinate neurons and to treat glial cell related and other neurodegenerative diseases or disorders or injuries or damage to the nervous system are provided. A method to manufacture neural cells depleted of A2B5 positive cells is also provided.
    Type: Grant
    Filed: November 9, 2010
    Date of Patent: July 16, 2019
    Assignee: Q THERAPEUTICS, INC.
    Inventors: Robert Sandrock, James T. Campanelli, Deborah A. Eppstein
  • Patent number: 10344256
    Abstract: Apparatuses, systems, and methods are provided for culturing a buoyant target tissue. Embodiments include a first surface configured to culture a first layer of supporting cells, and a second surface configured to culture a second layer of supporting cells. The first layer of supporting cells may be formed on a portion of the first surface and the second layer of supporting cells may be formed on a portion of the second surface. The buoyant target tissue may be added to the first layer of supporting cells. The second layer of supporting cells may be placed on the first layer of supporting cells such that the buoyant target tissue is sandwiched between the first layer of supporting cells and second layer of supporting cells.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: July 9, 2019
    Inventors: Frank Ho Pak Lau, Steven Douglas Scahill
  • Patent number: 10329527
    Abstract: Disclosed is a spheroid forming culture container using a temperature-sensitive glycol chitosan derivative and a spheroid forming method using the same. In the disclosed spheroid forming culture container, a surface of a culturing space is coated with a glycol chitosan derivative having reversible sol-gel transition characteristic depending on temperature.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: June 25, 2019
    Assignees: THE INDUSTRY & ACADEMIC COOPERTAION IN CHUNGNAM NATIONAL UNIVERSITY (IAC), KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Kang Moo Huh, Sun Woong Kang, Han Chang Kang, Hye Eun Shim, Ik Sung Cho, Myeong Ok Cho
  • Patent number: 10314944
    Abstract: The present application is directed to the field of implants comprising soft tissue for use in implantation in humans. The soft tissue implants of the present application are preferably obtained from xenograft sources. The present application provides a chemical process that neutralizes, removes or substantially reduces antigens from and sterilizes and/or strengthens xenograft implants. The present techniques yield soft tissue implants having superior structural, mechanical, and/or biochemical integrity. The present application is also directed to processes for treating xenograft implants comprising soft tissues such as tendons and ligaments, and to implants produced by such processes.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: June 11, 2019
    Assignee: RTI Surgical, Inc.
    Inventors: Pedro Daniel Pedroso, Amanda Michele Ely
  • Patent number: 10307442
    Abstract: A pharmaceutical composition for the prevention or treatment of a pulmonary disorder is provided. The composition contains mesenchymal stem cells showing improved proliferation and differentiation capacity which are characterized by the expression or non-expression of one or more particular cell markers. Also, provided is a method for obtaining mesenchymal stem cells showing improved proliferation and differentiation capacity based on the expression or non-expression of such cell markers. The mesenchymal stem cells having improved proliferation and differentiation capacity can be easily obtained from mesenchymal stem cells of various origins based on the expression or non-expression of CD26, CD49f, CD146 and EGFR. The mesenchymal stem cells thus obtained can be effectively used for the prevention or treatment of a pulmonary disorder such as, for example, pulmonary emphysema.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: June 4, 2019
    Assignee: MEDIPOST CO., LTD.
    Inventors: Yoon Sun Yang, Wonil Oh, Hye Jin Jin, Hong Bae Jeon, Miyeon Kim
  • Patent number: 10287541
    Abstract: Provided is a cell culture vessel characterized in that a surface to be in contact with cells is coated with a laminin fragment having integrin ?6?1 binding activity or a modified form thereof in a dry state, the laminin fragment being derived from at least one kind selected from laminin ?5?1?1 and laminin ?5?2?1, the cell culture vessel being any of the following: (1) a cell culture vessel of which a surface to be in contact with cells is coated only with a laminin fragment having integrin ?6?1 binding activity or a modified form thereof in a dry state; (2) a cell culture vessel of which a surface to be in contact with cells is coated with a laminin fragment having integrin ?6?1 binding activity or a modified form thereof in combination with a laminin fragment having no integrin ?6?1 binding activity in a dry state; and (3) a cell culture vessel of which a surface to be in contact with cells is coated with a laminin fragment having integrin ?6?1 binding activity or a modified form thereof in combinatio
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: May 14, 2019
    Assignee: OSAKA UNIVERSITY
    Inventors: Kiyotoshi Sekiguchi, Ko Tsutsui
  • Patent number: 10281451
    Abstract: This disclosure provides a method of determining the viability of at least one cell via quantification of nicotinamide adenine dinucleotide (phosphate) (NAD(P)H), flavin adenine dinucleotide (FAD), and/or collagen. The method includes the steps of contacting the at least one cell with light having a wavelength of from 700 to 900 nm, using two photon excitation, or from 335 to 400 nm, using one photon excitation, to induce an optical response from the NAD(P)H, FAD, and/or collagen and measuring the optical response. The method also includes the step of quantifying one or more of an amount, spatial localization, and/or time-dependent response of the NAD(P)H, FAD, and/or collagen utilizing the optical response.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: May 7, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Mary-Ann Mycek, Stephen Feinberg, Cynthia Marcelo, William Lloyd, Leng-Chun Chen, Shiuhyang Kuo, Hyungjin Myra Kim
  • Patent number: 10280470
    Abstract: Embodiments of the invention include methods and/or compositions for analysis of samples for C. difficile infection to determine whether or not an individual is at risk for having recurrent C. difficile infection or a CDI misdiagnosis. Methods include characterization of microflora composition from the gut, wherein alterations of the microflora gut composition are indicative of recurrence of infection. Methods include analysis of nucleic acids from the gut, such as 16S rRNA as being identifying of a particular bacteria in the analysis of bacterial populations of the gut.
    Type: Grant
    Filed: January 13, 2014
    Date of Patent: May 7, 2019
    Assignee: Baylor College of Medicine
    Inventors: Tor Savidge, Emily Hollister-Branton
  • Patent number: 10240217
    Abstract: A method including: (a) selectively reacting a first sugar in a mixture which includes at least one second sugar to form a product mixture comprising a product of said first sugar; (b) separating said product of said first sugar from said product mixture; and (c) separating at least one of said at least one second sugar from said product mixture.
    Type: Grant
    Filed: September 20, 2013
    Date of Patent: March 26, 2019
    Assignee: Virdia, Inc.
    Inventors: Robert Jansen, Aharon Eyal
  • Patent number: 10233478
    Abstract: A process is provided that is effective for reducing CO2 emissions, enhancing STY and/or increasing cell density. The process allows for utilization of syngas from different sources by controlling concentration levels of CO, CO2 and H2 in syngas provided to the fermentation and by controlling relative concentrations of CO, CO2 and H2 in the syngas provided to the fermentation. The process includes providing syngas to a first fermentation zone and fermenting the syngas. If the first fermentation zone off-gas includes about 4 mole % or more CO, then at least a portion of the first fermentor off-gas is provided to one or more subsequent fermentation zones.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: March 19, 2019
    Inventor: Ryan Senaratne
  • Patent number: 10227615
    Abstract: High conversion efficiency processes are disclosed for the anaerobic bioconversion of syngas to alcohol. The processes use bioreactors that have a non-uniform gas composition and a substantially uniform liquid composition such as deep tank bioreactors. By maintaining certain electron to carbon mole ratios in the syngas feed to the bioreactors and certain partial pressures of carbon dioxide in the off gas from the bioreactors, at least about 80 percent of the hydrogen and at least about 95 percent of the carbon monoxide in the feed can be consumed.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: March 12, 2019
    Assignee: Synata Bio, Inc.
    Inventors: Rathin Datta, Steven G. Calderone, Jianxin Du, Robert Hickey, Richard E. Tobey
  • Patent number: 10214751
    Abstract: The present invention provides a method for treatment of biomass material by fermentation, said method comprises a pre-treatment of the biomass material by thermal hydrolysis and wet explosion, resulting in an intermediate product having a dry matter concentration above 25% and temperature above 90° C. which is to be introduced to the fermentation, wherein a part of the content of the digestion tank used for the fermentation is recirculated and mixed with a part of the intermediate product from the pre-treatment.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: February 26, 2019
    Assignee: CAMBI TECHNOLOGY AS
    Inventors: Paal Jahre Nilsen, Hans Rasmus Holte
  • Patent number: 10202579
    Abstract: The present invention relates to the directed differentiation of mammalian pluripotent stem cells, especially human pluripotent stem (hPS) cells, into endodermal cells. In particular, the present invention relates to the treatment of mammalian pluripotent stem cells, especially hPS cells, with a DNA demethylating agent while undergoing differentiation into endodermal. The inventors have, as disclosed herein, found that exposing differentiating mammalian pluripotent stem cells, especially hPS cells, to a DNA demethylating agent leads to an improved morphology and improved yield of endodermal cells. The treatment with a DNA de-methylating agent also leads to a significant down-regulation of expression of the stem cell marker Oct4 and to an improved expression of endoderm specific markers, notably sox17, cxcr4 and hhex.
    Type: Grant
    Filed: November 28, 2013
    Date of Patent: February 12, 2019
    Assignee: Takara Bio Europe AB
    Inventors: Barbara Küppers-Munther, Josefina Edsbagge
  • Patent number: 10195231
    Abstract: Modified natural killer cells, pharmaceutical compositions comprising the modified natural killer cells and at least one pharmaceutically acceptable carrier or excipient, uses of the modified natural killer cells, and methods for identifying depleted natural killer cells and culturing the modified natural killer cells are provided.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: February 5, 2019
    Assignee: Academia Sinica
    Inventors: Nan-Shih Liao, Jan-Mou Lee
  • Patent number: 10197563
    Abstract: Disclosed is a three-dimensional (3-D) in vitro model for studying and subsequently treating cancer dormancy. The model is specifically useful in studying breast cancer and may be used for drug discovery because it maintains the breast cancer cells in a dormant state, unlike conventional two-dimensional (2-D) tissue culture plastic (TCP). Tumor-forming breast cancers cells were seeded on the 3-D model scaffolds and remained viable without proliferation. They also express stem cell markers typical for dormant cells. Dormant breast cancer cells also maintain their phenotype when seeded on the 3-D model unlike conventional 2-D models. The 3-D model includes a fibrous polycaprolactone with 30 wt. % hydroxyapatite. The 3-D model mimics the structure of bone tissue.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: February 5, 2019
    Assignees: New Jersey Institute of Technology, Rutgers, The State University of New Jersry
    Inventors: Treena Lynne Arinzeh, Pranela Rameshwar, Khadidiatou T. Guiro